Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Reusable Laryngeal Mask Airways can be used more than 40 times.

Goodman EJ, Christenson E, Douglas AM, Ziegler EJ, Lewis BR.

J Clin Anesth. 2008 Mar;20(2):109-15. doi: 10.1016/j.jclinane.2007.09.010.

PMID:
18410865
2.

The paxpress airway causes more pharyngeal irritation than the reusable laryngeal mask airway.

Goodman E, Ziegler EJ, Douglas AM.

AANA J. 2007 Apr;75(2):123-5.

PMID:
17471883
3.

Fungal arthritis of the knee caused by Candida parapsilosis in a kidney transplant recipient.

Vasquez JC, Hart M, Denney CF, Pedowitz R, Ziegler EJ.

J Clin Rheumatol. 2002 Jun;8(3):147-50.

PMID:
17041344
4.

The PAXpress airway causes more pharyngeal irritation than the reusable laryngeal mask airway.

Goodman EJ, Ziegler EJ, Douglas AM, Mulgaokar GD.

Anesth Analg. 2005 Jun;100(6):1862. No abstract available.

PMID:
15920237
5.

Amebic meningoencephalitis caused by Balamuthia mandrillaris: case report and review.

Denney CF, Iragui VJ, Uber-Zak LD, Karpinski NC, Ziegler EJ, Visvesvara GS, Reed SL.

Clin Infect Dis. 1997 Dec;25(6):1354-8. Review.

PMID:
9431377
6.

Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group.

Sprung CL, Eidelman LA, Pizov R, Fisher CJ Jr, Ziegler EJ, Sadoff JC, Straube RC, McCloskey RV.

Crit Care Med. 1997 Mar;25(3):383-7. Erratum in: Crit Care Med 1997 Jun;25(6):1092.

PMID:
9118650
7.

Anti-endotoxin monoclonal antibodies.

Ziegler EJ, Smith CR.

N Engl J Med. 1992 Apr 23;326(17):1165. No abstract available.

PMID:
1552929
8.

HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.

Smith CR, Straube RC, Ziegler EJ.

Infect Dis Clin North Am. 1992 Mar;6(1):253-66. Review.

PMID:
1578120
9.

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al.

N Engl J Med. 1991 Feb 14;324(7):429-36.

10.

Therapy of gram-negative sepsis in man with anti-endotoxin antibodies: a review.

Wortel CH, Ziegler EJ, van Deventer SJ.

Prog Clin Biol Res. 1991;367:161-78. Review. No abstract available.

PMID:
1924425
11.

Inhibition of lipopolysaccharide activation of 7OZ/3 cells by anti-lipopolysaccharide antibodies.

Kirkland TN, Ziegler EJ, Tobias P, Ward DC, Michalek SM, McGhee JR, Macher I, Urayama K, Appelmelk BJ.

J Immunol. 1988 Nov 1;141(9):3208-13.

PMID:
3262686
12.

Antiserum to endotoxin in hemorrhagic shock.

Pohlson EC, Suehiro A, Ziegler EJ, Suehiro G, McNamara JJ.

J Surg Res. 1988 Nov;45(5):467-71.

PMID:
3054323
13.

Protective antibody to endotoxin core: the emperor's new clothes?

Ziegler EJ.

J Infect Dis. 1988 Aug;158(2):286-90. No abstract available.

PMID:
2457055
14.

Tumor necrosis factor in humans.

Ziegler EJ.

N Engl J Med. 1988 Jun 9;318(23):1533-5. No abstract available.

PMID:
3259289
15.

Immunological intervention in endotoxin shock.

Ziegler EJ.

Prog Clin Biol Res. 1988;272:319-25. No abstract available.

PMID:
3293079
16.

Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5.

Baumgartner JD, O'Brien TX, Kirkland TN, Glauser MP, Ziegler EJ.

J Infect Dis. 1987 Jul;156(1):136-43. Erratum in: J Infect Dis 1987 Dec;156(6):1043.

PMID:
2439613
17.

Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies.

Kirkland TN, Colwell DE, Michalek SM, McGhee JR, Ziegler EJ.

J Immunol. 1986 Dec 1;137(11):3614-9.

PMID:
2431039
18.

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, van Melle G, Klauber MR, Vogt M, Muehlen E, Luethy R, Chiolero R, et al.

Lancet. 1985 Jul 13;2(8446):59-63.

PMID:
2861523
19.

An immunoprotective monoclonal antibody to lipopolysaccharide.

Kirkland TN, Ziegler EJ.

J Immunol. 1984 May;132(5):2590-2.

PMID:
6201551
20.

Treatment with anti-gram-negative antibodies.

McCutchan JA, Ziegler EJ.

Lancet. 1983 Oct 1;2(8353):802-3. No abstract available.

PMID:
6137643
22.

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI.

N Engl J Med. 1982 Nov 11;307(20):1225-30.

PMID:
6752708
23.

Lethal Haemophilus influenzae type b infection in mice.

Marks MI, Ziegler EJ, Douglas H, Corbeil LB.

Infection. 1982 Sep-Oct;10(5):261-6.

PMID:
6983499
24.

Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

Marks MI, Ziegler EJ, Douglas H, Corbeil LB, Braude AI.

J Clin Invest. 1982 Apr;69(4):742-9.

25.

Immunization against nosocomial infection.

Braude AI, Ziegler EJ, McCutchan JA, Douglas H.

Am J Med. 1981 Feb;70(2):463-6.

PMID:
7008592
26.

Successful treatment of human gram-negative bacteremia with antiserum against endotoxin core.

Ziegler EJ, McCutchan JA, Douglas H, Braude AI.

Trans Assoc Am Physicians. 1981;94:39-43. No abstract available.

PMID:
7046193
28.

Treatment of gram-negative bacteremia with antiserum to core glycolipid II. A controlled trial of antiserum in patients with bacteremia.

McCutchan JA, Ziegler EJ, Braude AI.

Eur J Cancer. 1979;15 Suppl:77-80. No abstract available.

PMID:
397064
29.

Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin.

Ziegler EJ, McCutchan JA, Braude AI.

Eur J Cancer. 1979;15 Suppl:71-6. No abstract available.

PMID:
397063
30.

Antiserum treatment of gram-negative bacteremia.

Braude AI, Ziegler EJ, McCutchan JA.

Schweiz Med Wochenschr. 1978 Dec 2;108(48):1872-6. Review.

PMID:
362528
31.

Neutralization of meningococcal endotoxin by antibody to core glycolipid.

Davis CE, Ziegler EJ, Arnold KF.

J Exp Med. 1978 Apr 1;147(4):1007-17.

32.

Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.

Braude AI, Ziegler EJ, Douglas H, McCutchan JA.

J Infect Dis. 1977 Aug;136 Suppl:S167-73.

PMID:
330776
33.

Candida septicemia.

Ziegler EJ.

West J Med. 1976 Jun;124(6):489. No abstract available.

34.

Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.

Ziegler EJ, McCutchan JA, Douglas H, Braude AI.

Trans Assoc Am Physicians. 1975;88:101-8.

PMID:
772922
35.

Experimental bacteremia due to Pseudomonas in agranulocytic animals.

Ziegler EJ, Douglas H, Braude AI.

J Infect Dis. 1974 Nov;130 Suppl(0):S145-8. No abstract available.

PMID:
4214311
36.
37.

Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

Ziegler EJ, Douglas H, Sherman JE, Davis CE, Braude AI.

J Immunol. 1973 Aug;111(2):433-8. No abstract available.

PMID:
4577881
38.

Iatrogenic administration of formaldehyde to hemodialysis patients.

Ogden DA, Myers LE, Eskelson CD, Ziegler EJ.

Proc Clin Dial Transplant Forum. 1973;3:135-40. No abstract available.

PMID:
4806630
39.

True blood flow and venous admixing in single needle dialysis: an in vitro study.

Gutch CF, Ziegler EJ, Cazee CR, Ogden DA.

Proc Clin Dial Transplant Forum. 1973;3:1-8. No abstract available.

PMID:
4806622
40.

A functional comparison of parallel plate dialyzers.

Ogden DA, Ziegler EJ, Cazee CR.

Proc Clin Dial Transplant Forum. 1971;1:21-4. No abstract available.

PMID:
5173662

Supplemental Content

Loading ...
Support Center